Depth and Rapidity of Response With Abrocitinib and Dupilumab in Patients With Moderate-to-Severe Atopic Dermatitis (AD) in JADE COMPARE

被引：0
|
作者：
Lio, Peter [1 ]
Boguniewicz, Mark [2 ,3 ]
Alexis, Andrew [4 ,5 ]
Lebwohl, Mark [6 ]
Reich, Kristian [7 ]
Pink, Andrew [8 ]
Kabashima, Kenji [9 ]
Bissonnette, Robert [10 ]
Nowicki, Roman [11 ]
Valdez, Hernan [12 ]
Zhang, Fan [12 ]
DiBonaventura, Marco [13 ]
Clibborn, Claire [12 ]
Cameron, Michael [12 ]
机构：
[1] Northwestern Univ, Feinberg Sch Med, Evanston, IL 60208 USA
[2] Natl Jewish Hlth, Denver, CO USA
[3] Univ Colorado, Sch Med, Boulder, CO 80309 USA
[4] Mt Sinai Morningside, New York, NY USA
[5] Mt Sinai West, New York, NY USA
[6] Icahn Sch Med Mt Sinai, New York, NY 10029 USA
[7] Univ Med Ctr Hamburg Eppendorf, Hamburg, Germany
[8] Kings Coll London, London, England
[9] Kyoto Univ, Grad Sch Med, Kyoto, Japan
[10] Innovaderm Res Inc, Montreal, PQ, Canada
[11] Med Univ Gdansk, Gdansk, Poland
[12] Pfizer Inc, New York, NY USA
[13] Pfizer Ltd, New York, NY USA
来源：
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY | 2021年 / 147卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
106
引用
收藏
页码：AB34 / AB34
页数：1
相关论文
共 50 条
  • [1] Depth and rapidity of response with abrocitinib and dupilumab in patients with moderate-to-severe atopic dermatitis in JADE COMPARE
    Lio, P.
    Boguniewicz, M.
    Alexis, A.
    Lebwohl, M.
    Reich, K.
    Pink, A.
    Kabashima, K.
    Bissonnette, R.
    Nowicki, R. J.
    Valdez, H.
    Zhang, F.
    DiBonaventura, M.
    Clibborn, C.
    Cameron, M. C.
    BRITISH JOURNAL OF DERMATOLOGY, 2021, 185 (03) : E138 - E139
  • [2] Effect of abrocitinib vs dupilumab and placebo on patient-reported outcomes (PROs) in moderate-to-severe atopic dermatitis (AD) in JADE COMPARE
    Yosipovitch, Gil
    Thyssen, Jacob P.
    Paul, Carle
    Kwatra, Shawn G.
    Chu, Chia-Yu
    Rojo, Ricardo
    Valdez, Hernan
    Feeney, Claire
    Zhang, Fan
    Myers, Daniela E.
    DiBonaventura, Marco
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB133 - AB133
  • [3] Rapidity of efficacy response with abrocitinib versus placebo and dupilumab in the head-neck region of adults with moderate-to-severe atopic dermatitis in the phase III JADE COMPARE study
    Alexis, A.
    Soong, W.
    de Bruin-Weller, M.
    Barbarot, S.
    Weidinger, S.
    Antinew, J.
    Biswas, P.
    Valdez, H.
    Clibborn, C.
    Yin, N.
    BRITISH JOURNAL OF DERMATOLOGY, 2022, 187 (01) : E41 - E41
  • [4] Rapidity of Improvement in Signs/Symptoms of Moderate-to-Severe Atopic Dermatitis by Body Region with Abrocitinib in the Phase 3 JADE COMPARE Study
    Alexis, Andrew
    de Bruin-Weller, Marjolein
    Weidinger, Stephan
    Soong, Weily
    Barbarot, Sebastien
    Ionita, Ileana
    Zhang, Fan
    Valdez, Hernan
    Clibborn, Claire
    Yin, Natalie
    DERMATOLOGY AND THERAPY, 2022, 12 (03) : 771 - 785
  • [5] Rapidity of Improvement in Signs/Symptoms of Moderate-to-Severe Atopic Dermatitis by Body Region with Abrocitinib in the Phase 3 JADE COMPARE Study
    Andrew Alexis
    Marjolein de Bruin-Weller
    Stephan Weidinger
    Weily Soong
    Sebastien Barbarot
    Ileana Ionita
    Fan Zhang
    Hernan Valdez
    Claire Clibborn
    Natalie Yin
    Dermatology and Therapy, 2022, 12 : 771 - 785
  • [6] TEMPORAL RESPONSE PATTERNS OF ABROCITINIB AND DUPILUMAB IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS: A POST HOC ANALYSIS OF THE JADE DARE TRIAL
    Trzeciak, Magdalena
    Chovatiya, Raj
    Geng, Bob
    Biswas, Pinaki
    Guler, Erman
    ACTA DERMATO-VENEREOLOGICA, 2023, 103 : 30 - 31
  • [7] Effect of abrocitinib and dupilumab on eosinophil levels in patients with moderate-to-severe atopic dermatitis
    Staumont-Salle, Delphine
    Barbarot, Sebastien
    Bouaziz, Jean David
    Chan, Chan
    Clibborn, Claire
    Du-Thanh, Aurelie
    Feeney, Claire
    Lejeune, Alexandre
    Misery, Laurent
    Nosbaum, Audrey
    Seneschal, Julien
    Soria, Angele
    Zhang, Fan
    JEADV CLINICAL PRACTICE, 2023, 2 (03): : 518 - 530
  • [8] Depth of response to abrocitinib in adults with moderate-to-severe atopic dermatitis (AD): Pooled analysis of monotherapy studies
    Staender, Sonja
    Bhatia, Neal
    Gooderham, Melinda J.
    Silverberg, Jonathan I.
    Thyssen, Jacob P.
    Biswas, Pinaki
    DiBonaventura, Marco
    Romero, William
    Farooqui, Saleem A.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB148 - AB148
  • [9] Onset and depth of response with abrocitinib vs. dupilumab in adults with moderate-to-severe atopic dermatitis: analysis of the phase IIIb JADE DARE clinical trial
    Reich, K.
    Valenzuela, F.
    Hong, H. C.
    Eyerich, K.
    Rice, Z. Pressley
    Bhambri, A.
    Guler, E.
    Zhang, F.
    Rojo, R.
    Chan, G.
    Clibborn, C.
    BRITISH JOURNAL OF DERMATOLOGY, 2022, 186 (04) : E170 - E170
  • [10] Switching from dupilumab to abrocitinib in patients with moderate-to-severe atopic dermatitis: an analysis of responders and nonresponders to dupilumab
    Silverberg, Jonathan, I
    Simpson, Eric L.
    Thyssen, Jacob P.
    Pink, Andrew E.
    Weidinger, Stephan
    Chan, Gary
    Lazariciu, Irina
    Clibborn, Claire
    Guler, Erman
    BRITISH JOURNAL OF DERMATOLOGY, 2023, 188
12345